Evotec’s biologics manufacturing unit, dubbed Just – Evotec Biologics, has expanded its multiyear biosimilar deal with Sandoz that the partners initially inked in May 2023. As part of the pact, Sandoz ...

With its blockbuster eye drug Eylea, Regeneron is already juggling between a recent FDA rejection and new competition. Meanwhile, biosimilar players are also eying a piece of the pie. Tuesday, ...

Sandoz is opening a new biosimilar development centre in Ljubljana, Slovenia, to strengthen and expand its in ‑ house ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: A sign marks the Novartis facility in Cambridge FRANKFURT (Reuters) -Novartis' generic-drugs unit Sandoz said on ...

Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, will host its 2026 capital markets day for investors and analysts: Tuesday, 8 September 13:30-17:00 UK time London ...

Sandoz is introducing Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz, the first and only interchangeable FDA-approved denosumab biosimilars and are approved to treat all indications of Amgen’s ...

Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trial Denosumab is indicated for ...

Nov 22 (Reuters) - Generic drug makers Teva Pharmaceutical Industries and Sandoz say they are planning a significant ramp-up in production of biosimilars – copies of high-priced drugs used to treat ...

Novartis' Sandoz has called on the US Supreme Court to review a lower court ruling that found biosimilar makers must wait an additional six months after US Food and Drug Administration (FDA) approval ...

Rebecca Guntern, President Europe, Sandoz, said: “Early treatment with disease-modifying therapies can have a significant impact on people living with multiple sclerosis and their potential future ...

Sandoz bought the Cimerli (ranibizumab-eqrn) business from Coherus Biosciences, the companies announced Monday morning. In January, Sandoz and Coherus entered into an agreement on a $170 million cash ...